This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis

Vera Bril, MD, FRCPC; Nicholas J. Silvestri, MD, FAAN; and Carolina Barnett-Tapia, MD, PhD

Published: May 24, 2022

Generalized myasthenia gravis (gMG) is a disease resulting from impaired neuromuscular transmission due to presence of antibodies that block acetylcholine receptors. Autoantibodies to acetylcholine receptors directly impair the activity of ion channels that conduct nerve impulses, and cross-link acetylcholine receptors resulting in complement-mediated destruction, further worsening functional impairment and patient quality of life. Although current treatments for gMG include thymectomy, immunosuppressive therapies, intravenous immunoglobulins, and plasmapheresis, among other strategies, none of these treatments reduces all immunoglobulin G subfractions. However, with the novel neonatal Fc receptor antagonist efgartigimod, levels of all immunoglobulin G subfractions are reduced, addressing an important aspect of the underlying pathophysiology of gMG. Through this program, clinicians will consider novel mechanisms in gMG therapy, learn to counsel patients on the changing landscape of gMG therapies, and find ways to incorporate the latest efficacy and safety data into practice.





This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Read the related Academic Highlights

Prim Care Companion CNS Disord. 2022;24(3):AR21018WC2C
To cite: Barnett-Tapia C, Bril V, and Silvestri NJ. A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis. Prim Care Companion CNS Disord. 2022;24(3):AR21018WC2C.
To share:
© 2022 Physicians Postgraduate Press, Inc.
From the Series: Like a Game of Chess, Every Move Matters: The Role of Antibodies in the Myasthenia Gravis Treatment Landscape

Volume: 24

Quick Links: